Premium
CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy
Author(s) -
Escolar Diana M.,
Buyse Gunnar,
Henricson Erik,
Leshner Robert,
Florence Julaine,
Mayhew Jill,
TesiRocha Carolina,
Gorni Ksenija,
Pasquali Livia,
Patel Kantilal M.,
McCarter Robert,
Huang Jennifer,
Mayhew Thomas,
Bertorini Tulio,
Carlo Jose,
Connolly Anne M.,
Clemens Paula R.,
Goemans Nathalie,
Iannaccone Susan T.,
Igarashi Masanori,
Nevo Yoram,
Pestronk Alan,
Subramony S. H.,
Vedanarayanan V. V.,
Wessel Henry
Publication year - 2005
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.20523
Subject(s) - duchenne muscular dystrophy , creatine , muscular dystrophy , glutamine , medicine , placebo , physical therapy , neuromuscular disease , clinical trial , physical medicine and rehabilitation , disease , biology , pathology , biochemistry , alternative medicine , amino acid
Abstract We tested the efficacy and safety of glutamine (0.6gm/kg/day) and creatine (5gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6‐month, double‐blind, placebo‐controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease‐modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated. Ann Neurol 2005;58:151–155